Core Points - 1933 Industries Inc. has announced that its unsecured convertible debentures issued in 2024, totaling approximately $2,598,000, will mature on December 31, 2025 [1] - The company has conducted a review of its financial position and operating performance, concluding that it currently lacks sufficient cash resources to repay the principal amount of the 2024 Debentures without significantly impairing its operational capabilities [1]

420 Investor launched in 2013, just ahead of Colorado legalizing for adult-use. We have moved the service to Seeking Alpha. Historically, we have provided great coverage of the sector with model portfolios, videos and written material to help investors learn about cannabis stocks, and we are excited to be doing it here!Cannabis stocks are still in a bear market that began almost five years ago, but they are now up year-to-date on potential rescheduling news. My favorite American cannabis operator, Green Thu ...

Core Viewpoint - Canopy Growth (CGC) shares have experienced a significant increase due to anticipated federal initiatives, including the reclassification of cannabis as a "Schedule III" drug and a potential Medicare pilot program for seniors [1][3]. Group 1: Stock Performance - CGC shares have risen by 90% compared to their low in late November [2]. - The stock is currently trading above its major moving averages (50-day, 100-day, 200-day), indicating bullish momentum as the company approaches 2026 [4]. Group 2: Federal Initiatives - The expected federal initiatives are likely to be transformative for cannabis stocks, facilitating institutional investments and easing tax burdens and banking restrictions, which could enhance revenue potential for CGC [3]. Group 3: Financial Strength - In the latest quarter, CGC narrowed its adjusted EBITDA loss to $3 million, reflecting positive momentum in the Canadian adult-use market [5]. - The company has approximately $300 million in liquidity, positioning it well for growth initiatives without immediate financial pressure [5]. Group 4: Strategic Acquisitions - Canopy Growth's recent acquisition of MTL Cannabis for about $179 million is expected to increase its domestic market share and contribute high-margin revenue [4]. Group 5: Historical Performance - CGC stock has historically performed well at the beginning of the year, averaging a 12% increase in January since 2015, supporting the case for maintaining exposure to the stock heading into 2026 [6][7].

SNDL (SNDL) shares gained nearly 12% on Wednesday. Dec. 16 following reports that President Donald Trump could reclassify cannabis as a “Schedule III” drug by the end of this week. The U.S. government is considering a policy shift that would offer some seniors access to cannabis products under Medicare coverage as well, the reports added. More News from Barchart SNDL stock has been a volatile investment this year. Despite a sharp rally on Tuesday, it’s down more than 25% versus its year-to-date high in ...

Core Insights - The cannabis industry has rapidly evolved beyond the regulatory frameworks that initially supported it, transitioning from a loosely regulated agricultural product to a diverse market encompassing medical treatments, wellness products, and adult-use consumption [1] Industry Overview - The cannabis market is now differentiated, indicating a significant expansion in its applications and consumer base [1] - The evolution of the industry reflects changing consumer preferences and regulatory landscapes, highlighting the need for updated support systems [1]

Core Viewpoint - Cannabis stocks experienced a rally following reports that President Trump is expected to sign an executive order rescheduling marijuana from Schedule I to Schedule III, which could lead to significant financial benefits for the cannabis sector [1]. Group 1: Tax Implications - Section 280E of the tax code currently prevents cannabis businesses from deducting standard business expenses, resulting in effective tax rates often exceeding 70% [2]. - Rescheduling cannabis to Schedule III would alleviate the burden of Section 280E, potentially allowing many cannabis businesses to achieve profitability for the first time [3]. Group 2: Market Reaction - Cannabis stocks were trading on above-average volumes and trending on social media as investors awaited an official statement from President Trump [5]. - Investors can track the sector through the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) and individual stocks of major companies such as Tilray Brands, Inc. (NASDAQ:TLRY), Canopy Growth Corp. (NASDAQ:CGC), and others [5]. Group 3: Legal Considerations - While rescheduling would ease research restrictions and tax burdens, it does not eliminate federal criminal penalties for recreational use, and marijuana would still remain illegal under federal law [4]. - The conflict between federal law and state laws that have legalized cannabis will continue to exist [4].

Core Viewpoint - The Trump administration is considering reclassifying marijuana from a Schedule I drug to a Schedule III drug, which would reduce restrictions and potentially enhance research opportunities in the cannabis industry [1][2]. Group 1: Market Performance - Shares of cannabis companies have seen significant increases following the news of potential reclassification, with notable jumps in stock prices since the announcement [3]. - Specific companies such as Tilray Brands Inc., Cresco Labs Inc., Canopy Growth Corp., Curaleaf Holdings Inc., and Trulieve Cannabis Corp. are highlighted as experiencing substantial stock performance improvements [4]. - For example, one company reported a five-day growth of 123.11% and a closing increase of 34.93% on Tuesday [5]. Group 2: Regulatory Context - Currently, marijuana is classified as a Schedule I drug, indicating it has no accepted medical use and a high potential for abuse, alongside substances like heroin and LSD [7]. - In contrast, Schedule III drugs, which include substances like anabolic steroids and ketamine, are considered to have a moderate to low potential for dependence [8]. - Reclassifying marijuana would not change its federal legality but would position it as less dangerous than Schedule II drugs, which include substances like cocaine and fentanyl [8]. Group 3: Historical Context - Despite the recent stock performance, cannabis stocks remain significantly lower than their highs in early 2021, during a peak period of excitement for marijuana reform [6].

TALLAHASSEE, Fla., Dec. 17, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the closing of a private placement of 10.5% Senior Secured Notes due 2030 (the "Notes") for aggregate gross proceeds of US$140.0 million (the "Offering"). The size of the Offering was increased given market demand for the Notes. The Notes were issued at 100% of face value and are senior secured obligatio ...

Marijuana may soon be reclassified as a schedule III drug, and the news has pushed cannabis ETFs, ahem, higher. The Trump administration’s potentially friendlier stance on bud follows a similar initiative to downgrade the drug from its current schedule I status, which eventually vaporized during the Biden administration. The likely rescheduling would mean more medical research for cannabinoids, and crucially for an industry operating in a gray legal area, it could dramatically reduce taxes. “There are s ...

Core Viewpoint - Vireo Growth Inc. is expanding its retail presence in Colorado by acquiring 17 dispensaries from PharmaCann Inc., bringing its total to 41 dispensaries in the state, which strengthens its leadership position in the adult-use retail market [1][2]. Group 1: Transaction Details - The total consideration for the acquisition is approximately $49.0 million, payable in subordinate voting shares at closing, along with the assumption of certain liabilities [2]. - The share consideration will be adjusted based on inventory levels and trade payables of the acquired dispensaries, and will be subject to customary resale restrictions under Canadian securities law [2]. - A Management Services Agreement has been established, allowing one of Vireo's subsidiaries to manage the acquired dispensaries until the closing, pending necessary regulatory approvals [2]. Group 2: Strategic Implications - The CEO of Vireo, John Mazarakis, emphasized that this transaction aligns with the company's strategy of growth through accretive mergers and acquisitions, complementing other recent acquisitions in Colorado [3]. - Vireo was founded in 2014 as a pioneering medical cannabis company, focusing on building a disciplined and execution-oriented platform in the industry [3].